Influx Healthtech Limited — Investor Meet, 18-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Influx Healthtech reported robust H1 FY26 financial results, with revenue up 39% to INR 66.8 Cr, EBITDA rising 61% to INR 14.7 Cr (22% margin), and PAT growing 78% to INR 10 Cr (15% margin). Management aims to double the business by FY27, targeting INR 450-500 Cr by FY29, driven by strategic capacity expansions in nutraceutical, veterinary, and new beverage lines. IPO funds are being deployed to increase production 2.5x from FY25 levels. The company is actively diversifying into high-margin cosmetics and fast-growing pet care, focusing on global market presence and quality certifications. Management expresses confidence in sustaining margins and growth.